This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Jim Cramer's 'Mad Money' Recap: Let's Hear It for the Bull

 

 

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.


NEW YORK ( TheStreet) -- Today's relief rally in the markets is a good start, Jim Cramer said Tuesday on  Mad Money, but for the rally to continue there are a bunch of things that have to go the bulls' way.

Cramer explained that the markets have been pushed lower buy the pending Alibaba initial public offering, which forced big money managers to liquidate some of their holdings to make room for this fast-growing Chinese Internet play. But now that fund managers are ready for action, the markets can rebound -- but only if a few other things go right.

Cramer said that the markets first need to hear from the Federal Reserve. The market needs to hear language that the central bankers are flexible, basing their interest rate decisions on data and not on a rigid timeline. If the markets know the Fed has their back, the rally can continue.

Read More: 10 Stocks Carl Icahn Loves in 2014

The markets also need the Alibaba IPO to go off without a hitch. Cramer said if shares see more than a modest rally the fearmongers will be out in force, likening the deal to the dot-com bust of 2001.

Next, the markets need to see the European Central Bank's bond buying program to stabilize the euro and stop the U.S. dollar's strengthening. The markets could also benefit from oil prices stabilizing, Cramer said.

Finally, the markets need companies to keep doing what they've been doing, which is rewarding shareholders with acquisitions, breakups, dividends and buybacks.

If just some of these can happen, the rally will continue, Cramer concluded. If not, then we could be in for a rocky ride.

Tips From Beyond the Business Pages

Sometimes the best investment ideas come from the strangest of places, Cramer told viewers. That's why investors need to read a lot more than just the business pages.

Case in point: the Sept 15 issue of The New Yorker featured an article entitled "The Transformation" that detailed the promise of controlling cancer without killing it.

Cramer said this article explored the exciting new treatments currently under development at Agios Pharmaceuticals (AGIO) , which rather than targeting and killing cancer directly merely changes its metabolism, rendering it harmless.

Cramer cautioned that Agios' drug, AG-120, is only in Phase I testing and has only been administered to a few dozen patients. But the results so far have been staggering, which makes Agios a continued buy.

Cramer first recommended Agios after its July 2013 IPO, and he continues to like the company's research and its partnership with Celgene (CELG) , which owns 11.6% of the company.

Read More: Why the Fed Should Hold Off Signaling Higher Rates for Now

With drugs still years away, Cramer said Agios trades on news and catalysts and not on any traditional metrics such as earnings. But with those caveats in mind, the company shows a lot of promise.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,131.97 +100.83 0.59%
S&P 500 1,998.98 +14.85 0.75%
NASDAQ 4,552.7590 +33.8570 0.75%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs